Aminacrine

Aminacrine

SCHEMBL4907467

Nc1c2ccccc2nc2ccccc12.[N]

nearest known ligand 0.95

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 6/20 0.95
ACHE P22303 6/20 0.95
ALDH1A1 P00352 5/20 0.95
KDM4E B2RXH2 3/20 0.95
HPGD P15428 3/20 0.95
GLA P06280 2/20 0.95
CASP1 P29466 2/20 0.95
CASP7 P55210 2/20 0.95
SMN1; SMN2 Q16637 2/20 0.95
MAOA P21397 2/20 0.95
CHRM2 P08172 2/20 0.95
ADRA2A P08913 2/20 0.95
ADORA3 P0DMS8 2/20 0.95
CHRM1 P11229 2/20 0.95
SLC6A2 P23975 2/20 0.95
OPRM1 P35372 2/20 0.95
KCNH2 Q12809 2/20 0.95
NQO2 P16083 1/20 0.95
DRD1 P21728 1/20 0.95
ADRA1A P35348 1/20 0.95

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Aminacrine SCHEMBL14999 0.97 HSD17B10 (1.00) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL29354393 0.97 HSD17B10 (1.00) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL30355377 0.95 HSD17B10 (0.95) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL14482032 0.95 HSD17B10 (0.95) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL4344206 0.95 HSD17B10 (0.95) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL635597 0.95 RAB9A (1.00) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL31237441 0.95 RAB9A (1.00) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL18989123 0.95 HSD17B10 (0.95) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL635598 0.95 RAB9A (1.00) HSD17B10ACHEALDH1A1KDM4EHPGD
Aminacrine SCHEMBL28190415 0.95 HSD17B10 (0.95) HSD17B10ACHEALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9193687-B2 Phenyl N-mustard linked to DNA-affinic molecules or water-soluble aryl rings, method and their use as cancer therapeutic agents ACADEMIA SINICA (TW) 2015-11-24 US disclosed
US-20130178494-A1 PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS ACADEMIA SINICA (TW) 2013-07-11 US disclosed
US-8222297-B2 e.g. 1-[3-(acridin-9-ylamino)-5-hydroxymethylphenyl]-3-{4-[bis(2-chloroethyl)amino]phenyl}urea; anticarcinogenic agent; improved chemical stability and efficacy; brain tumor, breast cancer, colon cancer, leukemia, and neuroblastoma ACADEMIA SINICA (TW) 2012-07-17 US disclosed
US-20080171765-A1 Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents ACADEMIA SINICA (TW) 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171765-A1 Aniline or phenol mustards linked to DNA-affinic molecules or water-soluble aromatic rings and their use as cancer therapeutic agents WEE1, PCNA, ATIC HSD17B10 3037/4885ACHE 1385/4885ALDH1A1 1144/4885
US-20130178494-A1 PHENYL N-MUSTARD LINKED TO DNA-AFFINIC MOLECULES OR WATER-SOLUBLE ARYL RINGS, METHOD AND THEIR USE AS CANCER THERAPEUTIC AGENTS PCNA, WEE1, UNG HSD17B10 4815/4885ACHE 4494/4885ALDH1A1 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.